China (Mainland)
SARMS RAD-140 CAS:1182367-47-0 CAS NO.1182367-47-0
- FOB Price: USD: 1.00-11.00 /Metric Ton Get Latest Price
- Min.Order: 1 Gram
- Payment Terms: L/C,D/A,D/P,T/T,Other
- Available Specifications:
99(1-10)Metric Ton99(1-10)Metric Ton
- Product Details
Keywords
- RAD-140
- 1182367-47-0
- SARMS
Quick Details
- ProName: SARMS RAD-140 CAS:1182367-47-0
- CasNo: 1182367-47-0
- Molecular Formula: C20H16ClN5O2
- Appearance: white powder
- Application: pharmaceutical intermediate
- DeliveryTime: stocking
- PackAge: confirms to customer
- Port: china
- ProductionCapacity: 1 Kilogram/Day
- Purity: 99%
- Storage: shade
- Transportation: confirms to customer
- LimitNum: 1 Gram
- Moisture Content: 0.5%
- Impurity: 0.1%
Superiority
RAD140, from its internal nonsteroidal selective
androgen receptor modulator (“SARM”) discovery program, for full preclinical development as a
potential therapy for the treatment of age-related muscle loss (sarcopenia) and other
musculoskeletal conditions such as osteoporosis. Radius selected RAD140 from a series of
promising SARMs after it demonstrated exceptional selectivity for anabolic activity in well-
validated in vivo models. Radius expects to complete formal toxicology studies that will allow
This makes its usage significantly safer and more effective compared to traditional prohormones and anabolic steroids.
Details
|
AICAR |
2627-69-2 |
acts by entering nucleoside pools, significantly increasing levels of adenosine during periods of ATP breakdown |
|
841205-47-8 |
medical prescription for prevention of cachexia, atrophy, and sarcopenia and for Hormone or Testoserone Replacement Therapy. |
|
|
MK-677 |
15972-10-0 |
A growth hormone secretagogue, treatment of obesity, a promising therapy for the treatment of frailty in the elderly |
|
LGD-4033 |
1165910-22-4 |
pharmacological profile similar to that of enobosarm, Ostarine,MK-2866 |
|
GW501516 |
317318-70-0 |
For obesity, diabetes, dyslipidemia and cardiovascular disease |
|
Andarine(S4) |
401900-40-0 |
partial agonist, intended mainly for treatment of benign prostatic hypertrophy |
|
SR9009 |
1379686-30-2 |
under development at The Scripps Research Institute (TSRI), increases the level of metabolic activity in skeletal muscles of mice |
|
SR9011 |
1379686-30-2 |
For obesity, diabetes, dyslipidemia and cardiovascular disease |
|
1182367-47-0 |
New generation for gaining mass and cutting edges |
|
|
366508-78-3 431579-34-9 |
a SARM and myostatin inhibitor in one |
|
|
GHRP-2 |
158861-67-7 |
Growth Hormone Releasing Peptide-2 |
|
GHRP-6 |
87616-84-0 |
Growth Hormone Releasing Peptide-6 |
|
TB500 |
107761-42-2 |
Thymosin beta 4 |
|
SM130,686 |
/ |
/ |